@UMKCBioMed In patients with Huntington’s disease, pridopidine twice daily did not improve the UHDRS -TMS at week 26 compared with placebo with no new safety or tolerability concerns emerged #UMKCRCT https://t.co/fQC2REHwcj https://t.co/EX3s5G7bm3
Pridopidine did not improve the symptoms of Huntington's disease compared with the placebo. Also, the results of secondary or tertiary analyses in previous trials were not replicated! #UMKCRCT https://t.co/iIYqO3B11P
Pridopidine does not reduce motor impairment in patients with Huntington disease, according to PRIDE-HD: a phase II, randomised, placebo-controlled, multicentre, dose-ranging study https://t.co/yq2DzNBkdI